156 related articles for article (PubMed ID: 15453342)
1. [Entecavir therapy against hepatitis B].
Kato N; Omata M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():340-4. PubMed ID: 15453342
[No Abstract] [Full Text] [Related]
2. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
[TBL] [Abstract][Full Text] [Related]
3. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.
Ismail AM; Sharma OP; Kumar MS; Eapen CE; Kannangai R; Abraham P
Antiviral Res; 2013 May; 98(2):209-16. PubMed ID: 23485939
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?
Zoulim F
Hepatology; 2006 Dec; 44(6):1404-7. PubMed ID: 17133478
[No Abstract] [Full Text] [Related]
5. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
Cheng PN; Chang TT
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B.
Scotto G; D'Addiego G; Giammario A; Campanale F; Fazio V
Liver Int; 2012 Jan; 32(1):171-2. PubMed ID: 22098064
[No Abstract] [Full Text] [Related]
7. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
8. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
9. Entecavir for the long-term treatment of chronic hepatitis B.
Gonzalez SA; Keeffe EB
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1053-62. PubMed ID: 19883325
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
Asselah T; Marcellin P
Clin Liver Dis; 2013 Aug; 17(3):445-50. PubMed ID: 23905815
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
[TBL] [Abstract][Full Text] [Related]
12. Five-year data released for entecavir.
AIDS Patient Care STDS; 2008 Apr; 22(4):349. PubMed ID: 18422464
[No Abstract] [Full Text] [Related]
13. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
[TBL] [Abstract][Full Text] [Related]
14. Entecavir for the treatment of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis B: focus on telbivudine.
Lui YY; Chan HL
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):259-68. PubMed ID: 19344240
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
18. [Hepatitis B virus resistance to entecavir].
Hidalgo-Tenorio C; Rivero M; Alvarez M; García F
Med Clin (Barc); 2012 Jul; 139(5):228-9. PubMed ID: 22401720
[No Abstract] [Full Text] [Related]
19. [Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].
LI H; WANG ZY; ZHANG DZ; SHI XF; ZHOU Z; REN H
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):338-41. PubMed ID: 19497197
[TBL] [Abstract][Full Text] [Related]
20. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
